S&P 500   3,897.71 (-0.11%)
DOW   31,570.49 (+0.11%)
QQQ   322.67 (-0.28%)
AAPL   127.06 (-0.57%)
MSFT   235.40 (-0.65%)
FB   265.35 (+0.17%)
GOOGL   2,081.27 (+0.56%)
TSLA   709.93 (-1.18%)
AMZN   3,147.00 (+0.03%)
NVDA   548.21 (-0.99%)
BABA   240.79 (-0.37%)
CGC   36.03 (+3.74%)
GE   13.09 (-0.15%)
MU   94.10 (-0.70%)
NIO   45.03 (-9.51%)
AMD   85.95 (-0.51%)
T   28.27 (+0.64%)
F   12.09 (+0.92%)
ACB   11.73 (+6.25%)
DIS   196.45 (+0.75%)
BA   223.23 (-0.52%)
NFLX   551.57 (+0.17%)
BAC   35.88 (+0.25%)
S&P 500   3,897.71 (-0.11%)
DOW   31,570.49 (+0.11%)
QQQ   322.67 (-0.28%)
AAPL   127.06 (-0.57%)
MSFT   235.40 (-0.65%)
FB   265.35 (+0.17%)
GOOGL   2,081.27 (+0.56%)
TSLA   709.93 (-1.18%)
AMZN   3,147.00 (+0.03%)
NVDA   548.21 (-0.99%)
BABA   240.79 (-0.37%)
CGC   36.03 (+3.74%)
GE   13.09 (-0.15%)
MU   94.10 (-0.70%)
NIO   45.03 (-9.51%)
AMD   85.95 (-0.51%)
T   28.27 (+0.64%)
F   12.09 (+0.92%)
ACB   11.73 (+6.25%)
DIS   196.45 (+0.75%)
BA   223.23 (-0.52%)
NFLX   551.57 (+0.17%)
BAC   35.88 (+0.25%)
S&P 500   3,897.71 (-0.11%)
DOW   31,570.49 (+0.11%)
QQQ   322.67 (-0.28%)
AAPL   127.06 (-0.57%)
MSFT   235.40 (-0.65%)
FB   265.35 (+0.17%)
GOOGL   2,081.27 (+0.56%)
TSLA   709.93 (-1.18%)
AMZN   3,147.00 (+0.03%)
NVDA   548.21 (-0.99%)
BABA   240.79 (-0.37%)
CGC   36.03 (+3.74%)
GE   13.09 (-0.15%)
MU   94.10 (-0.70%)
NIO   45.03 (-9.51%)
AMD   85.95 (-0.51%)
T   28.27 (+0.64%)
F   12.09 (+0.92%)
ACB   11.73 (+6.25%)
DIS   196.45 (+0.75%)
BA   223.23 (-0.52%)
NFLX   551.57 (+0.17%)
BAC   35.88 (+0.25%)
S&P 500   3,897.71 (-0.11%)
DOW   31,570.49 (+0.11%)
QQQ   322.67 (-0.28%)
AAPL   127.06 (-0.57%)
MSFT   235.40 (-0.65%)
FB   265.35 (+0.17%)
GOOGL   2,081.27 (+0.56%)
TSLA   709.93 (-1.18%)
AMZN   3,147.00 (+0.03%)
NVDA   548.21 (-0.99%)
BABA   240.79 (-0.37%)
CGC   36.03 (+3.74%)
GE   13.09 (-0.15%)
MU   94.10 (-0.70%)
NIO   45.03 (-9.51%)
AMD   85.95 (-0.51%)
T   28.27 (+0.64%)
F   12.09 (+0.92%)
ACB   11.73 (+6.25%)
DIS   196.45 (+0.75%)
BA   223.23 (-0.52%)
NFLX   551.57 (+0.17%)
BAC   35.88 (+0.25%)
Log in
NASDAQ:SGMO

Sangamo Therapeutics Stock Forecast, Price & News

$11.83
-0.16 (-1.33 %)
(As of 03/2/2021 09:42 AM ET)
Add
Compare
Today's Range
$11.74
Now: $11.83
$12.01
50-Day Range
$11.19
MA: $14.15
$16.21
52-Week Range
$4.81
Now: $11.83
$19.43
Volume1,302 shs
Average Volume1.58 million shs
Market Capitalization$1.69 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.97
Sangamo Therapeutics, Inc., a biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression. Its therapeutic products that are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; ST-920 gene therapy for Fabry disease; ST-101 gene therapy for phenylketonuria; ST-400 and BIVV-003 for the treatment of hemoglobinopathies; SB-913 for the treatment of Mucopolysaccharidosis type II; SB-318 for the treatment of Mucopolysaccharidosis type I; and SB-FIX for the treatment of hemophilia B. The company has collaborative and strategic partnerships with Biogen Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.
Sangamo Therapeutics logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SGMO
CUSIP80067710
Phone510-970-6000
Employees354
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$102.43 million
Book Value$3.73 per share

Profitability

Net Income$-95,190,000.00

Miscellaneous

Market Cap$1.69 billion
Next Earnings Date5/10/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.33 out of 5 stars

Medical Sector

675th out of 1,966 stocks

Biological Products, Except Diagnostic Industry

90th out of 177 stocks

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$11.83
-0.16 (-1.33 %)
(As of 03/2/2021 09:42 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SGMO News and Ratings via Email

Sign-up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sangamo Therapeutics (NASDAQ:SGMO) Frequently Asked Questions

Is Sangamo Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Sangamo Therapeutics stock.
View analyst ratings for Sangamo Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Sangamo Therapeutics?

Wall Street analysts have given Sangamo Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sangamo Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Sangamo Therapeutics' next earnings date?

Sangamo Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Sangamo Therapeutics
.

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) announced its quarterly earnings data on Wednesday, February, 24th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.11. Sangamo Therapeutics had a negative trailing twelve-month return on equity of 16.32% and a negative net margin of 51.51%.
View Sangamo Therapeutics' earnings history
.

How has Sangamo Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Sangamo Therapeutics' stock was trading at $7.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SGMO stock has increased by 68.5% and is now trading at $11.83.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SGMO?

5 Wall Street analysts have issued 12 month price targets for Sangamo Therapeutics' stock. Their forecasts range from $11.00 to $25.00. On average, they anticipate Sangamo Therapeutics' stock price to reach $18.00 in the next year. This suggests a possible upside of 52.2% from the stock's current price.
View analysts' price targets for Sangamo Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Sangamo Therapeutics' key executives?

Sangamo Therapeutics' management team includes the following people:
  • Dr. Alexander D. Macrae, CEO, Pres & Director (Age 58, Pay $1.14M)
  • Mr. Sung H. Lee, Exec. VP & CFO (Age 49, Pay $320.19k)
  • Mr. Gary H. Loeb, Exec. VP, Gen. Counsel, Chief Compliance Office & Sec. (Age 51, Pay $487.88k)
  • Dr. R. Andrew Ramelmeier Ph.D., Exec. VP of Technical Operations (Age 59, Pay $542.21k)
  • Ms. Prathyusha Duraibabu, VP of Fin. & Principal Accounting Officer (Age 41)
  • Ms. Aron Feingold, Head of Corp. Communications & Investor Relations Officer
  • Ms. Whitney Jones, Sr. VP & Chief People Officer
  • Dr. Nathalie Dubois-Stringfellow, Sr. VP of Product Devel. & Management
  • Ms. Heather Erickson, Chief of Staff
  • Dr. Duncan McKay, Sr. VP & GM of Europe

What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO?

10 employees have rated Sangamo Therapeutics CEO Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among Sangamo Therapeutics' employees.

Who are some of Sangamo Therapeutics' key competitors?

What other stocks do shareholders of Sangamo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

Who are Sangamo Therapeutics' major shareholders?

Sangamo Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.76%), Credit Suisse AG (2.41%), Dimensional Fund Advisors LP (1.67%), JPMorgan Chase & Co. (1.26%), Northern Trust Corp (1.02%) and Nuveen Asset Management LLC (1.02%). Company insiders that own Sangamo Therapeutics stock include H Stewart Parker, Joseph S Zakrzewski, Kathy Yi, Rolf Andrew Ramelmeier, Saira Ramasastry and Stephen George Dilly.
View institutional ownership trends for Sangamo Therapeutics
.

Which institutional investors are selling Sangamo Therapeutics stock?

SGMO stock was sold by a variety of institutional investors in the last quarter, including Great Lakes Advisors LLC, BlackRock Inc., Baker BROS. Advisors LP, ClariVest Asset Management LLC, Mackenzie Financial Corp, Wells Fargo & Company MN, SG Americas Securities LLC, and Northern Trust Corp. Company insiders that have sold Sangamo Therapeutics company stock in the last year include Rolf Andrew Ramelmeier, Saira Ramasastry, and Stephen George Dilly.
View insider buying and selling activity for Sangamo Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Sangamo Therapeutics stock?

SGMO stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Voloridge Investment Management LLC, Morgan Stanley, Credit Suisse AG, Nordea Investment Management AB, State of New Jersey Common Pension Fund D, UBS Asset Management Americas Inc., and First Trust Advisors LP. Company insiders that have bought Sangamo Therapeutics stock in the last two years include H Stewart Parker, and Joseph S Zakrzewski.
View insider buying and selling activity for Sangamo Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sangamo Therapeutics' stock price today?

One share of SGMO stock can currently be purchased for approximately $11.83.

How much money does Sangamo Therapeutics make?

Sangamo Therapeutics has a market capitalization of $1.69 billion and generates $102.43 million in revenue each year. The biopharmaceutical company earns $-95,190,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis.

How many employees does Sangamo Therapeutics have?

Sangamo Therapeutics employs 354 workers across the globe.

What is Sangamo Therapeutics' official website?

The official website for Sangamo Therapeutics is www.sangamo.com.

Where are Sangamo Therapeutics' headquarters?

Sangamo Therapeutics is headquartered at 7000 MARINA BLVD, BRISBANE CA, 94005.

How can I contact Sangamo Therapeutics?

Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected]


This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.